# Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)

> **NCT05186974** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 193 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Sacituzumab Govitecan-hziy (SG)
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05186974
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-05-30
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 193 (ACTUAL)
- **Last updated:** 2026-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05186974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05186974, "Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05186974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*